TheStreet Network:
TheStreet
|
MainStreet
|
BankingMyWay
|
RealMoney
Home
About Stockpickr
|
How to Use
Portfolios
Professional
Warren Buffett
George Soros
T. Boone Pickens
Carl Icahn
» Most-Viewed
» Recently Updated
Stockpickr Spotlight
4 Turnarounds Poised for better days Ahead
Zombie Apocalypse Portfolio
2 Stocks That Will Double in 2013
Less-Volatile Stocks for a Volatile World
5 Small-Cap Bank Stock Plays for 2013 From Credit Suisse
» More Spotlight Portfolios
User Generated
Recently Updated
Tools
Market Indicators
Top % Gainers
Top % Losers
52-Week Highs
52-Week Lows
Rising on Unusual Volume
Unusual Options Activity
Upgrades and Downgrades
Analyst Upgrades
Analyst Downgrades
TheStreet Ratings Upgrades
TheStreet Ratings Downgrades
Daily Lists
Cramer's "Lightning Round"
Insider Buying
Insider Selling
Earnings Announcements
Ex-Dividend Stocks
Dogs of the Dow
Articles
4 Tech Stocks to Trade (or Not)
3 Big Stocks to Trade (or Not)
5 Stocks Setting Up to Break Out
5 Dividend Stocks That Want to Pay You More
5 Stocks Under $10 Set to Soar
» More Articles
My Stockpickr
Log In
|
Join for Free
Stock Game
Health Care: Drugs
Vertex Pharmaceuticals (VRTX: NASDAQ)
$79.49
1.60 | 2.05%
05/17/13 - 04:00 PM ET
Quote
Ratings
Earnings
Fundamentals
Options Chain
Advanced Chart
Balance Sheet
Cash Flow
Income Statement
Growth Rates
Major Holders
Ratio Comparison
Portfolios with
VRTX
Portfolio Name
User Type
User
DC
User
Portfolio
Pro
Daniel Loeb - Third Point
User
Mike Fatah's Mega Stock Por...
Contributor
10 Companies That Prove Sto...
Contributor
Relative Strength Trades fo...
Contributor
Earnings Short Squeeze Play...
Pro
D.E. Shaw
Contributor
Earnings Short Squeeze Play...
Contributor
10 Hep C Stocks on Wall Str...
View All
Latest
VRTX
Headlines from TheStreet
Vertex Pharmaceuticals (VRTX): Today's Featured Health Care Laggard
05.16.13 | 05:05 pm
3 Stocks Underperforming Today In The Drugs Industry
05.15.13 | 01:05 pm
3 Stocks Improving Performance Of The Health Care Sector
05.06.13 | 01:05 pm
Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard
05.03.13 | 05:05 pm
Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard
04.26.13 | 05:04 pm
Vertex CFO Rings Register On $35 Million Insider Sale
04.24.13 | 07:04 am
'Mad Money' Lightning Round: Apache Is a Dog
04.24.13 | 06:04 am
Cramer's 'Mad Money' Recap: Looking for Winners in Unlikely Places
04.23.13 | 08:04 pm
4 Stocks Pushing The Drugs Industry Downward
04.22.13 | 01:04 pm
Vertex Stock Falls On Unusually High Volume (VRTX)
04.22.13 | 12:04 pm
More Financial News for VRTX
Press Releases for
VRTX
VX-787 Showed Significant Antiviral Activity And Reduced The Severity And Duration Of Influenza Symptoms In Phase 2 Challenge Study
- Business Wire 03.04.13 | 08:03 am
Vertex Announces Webcasts Of Its Presentations At Two Investor Conferences
- Business Wire 02.27.13 | 04:02 pm
Vertex Announces Initiation Of Pivotal Phase 3 Program Of VX-809 In Combination With Ivacaftor For The Treatment Of People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation
- Business Wire 02.26.13 | 04:02 pm
Republic Of Ireland Approves Funding For KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis, For People With A Specific Genetic Mutation (G551D)
- Business Wire 02.01.13 | 12:02 pm
Vertex Reports Full-Year And Fourth Quarter 2012 Financial Results And Provides Updates On Key Development Programs
- Business Wire 01.29.13 | 04:01 pm
Vertex To Report Fourth Quarter And Full Year 2012 Financial Results On Tuesday, January 29
- Business Wire 01.15.13 | 04:01 pm
Vertex Outlines Corporate Strategy And Defines Key 2013 Business Priorities
- Business Wire 01.06.13 | 05:01 pm
NHS In England Funds KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis, For People With A Specific Genetic Mutation (G551D)
- Business Wire 12.19.12 | 09:12 am
Vertex Announces Update To U.S. Prescribing Information For INCIVEK® (telaprevir)
- Business Wire 12.19.12 | 08:12 am
Health Canada Approves KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People With A Specific Genetic Mutation (G551D)
- Business Wire 12.03.12 | 08:12 am
See All Press Releases
Partner Headlines for
VRTX
Market Close Report: NASDAQ Composite index closes at 3,206.06 up 39.70 points
- NASDAQ 04.19.13 | 08:04 pm
Stocks Up, Dow Turns Positive; Leaders Catch An Updraft
- Investor's Business Daily 04.19.13 | 12:04 pm
UPDATE: Credit Suisse Raises PT on Vertex Pharmaceuticals on Cystic Fibrosis Franchise De-Risking
- Benzinga 04.19.13 | 09:04 am
Futures Geared For Higher Open; Vertex, Google, Chipotle Rumble
- Investor's Business Daily 04.19.13 | 08:04 am
Stocks Take Another Drubbing, But Google Rises After Hours
- Investor's Business Daily 04.18.13 | 05:04 pm
Regeneron Pharmaceuticals Inc (REGN): Today's Most Compelling Buy
- NASDAQ 03.14.13 | 04:03 pm
Market Close Report: NASDAQ Composite index closes at 3,244.37 up 12.28 points
- NASDAQ 03.08.13 | 09:03 pm
Gilead Stock Hits New High As HCV Drug Keeps Rocking
- Investor's Business Daily 02.19.13 | 04:02 pm
RIM, Green Mountain and Other Top Performing Nasdaq Stocks in November
- Benzinga 12.01.12 | 01:12 pm
Celgene, Regeneron Pharmaceutical Lead Biomed Group
- Investor's Business Daily 11.30.12 | 05:11 pm
Refresh Stock Quote for Vertex Pharmaceuticals - VRTX
Ratings Moves: AIR,...
Thomson Reuters/Uni...
Tilson: AIG Is No V...
Home
About Stockpickr
How to Use
Join for FREE
STOCK GAME
Portfolios
Professional
Warren Buffett
George Soros
T. Boone Pickens
Carl Icahn
Most-Viewed
Recently Updated
Stockpickr Spotlight
4 Turnarounds Poised for better days Ahead
Zombie Apocalypse Portfolio
2 Stocks That Will Double in 2013
Less-Volatile Stocks for a Volatile World
5 Small-Cap Bank Stock Plays for 2013 From Credit Suisse
More Spotlight Portfolios
User Generated
Recently Updated
Tools
Market Indicators
Top % Gainers
Top % Losers
52-Week Highs
52-Week Lows
Rising on Unusual Volume
Unusual Options Activity
Upgrades and Downgrades
Analyst Upgrades
Analyst Downgrades
TheStreet Ratings Upgrades
TheStreet Ratings Downgrades
Daily Lists
Cramer's "Lightning Round"
Insider Buying
Insider Selling
Earnings Announcements
Ex-Dividend Stocks
Dogs of the Dow
Articles
4 Tech Stocks to Trade (or Not)
3 Big Stocks to Trade (or Not)
5 Stocks Setting Up to Break Out
5 Dividend Stocks That Want to Pay You More
5 Stocks Under $10 Set to Soar
More Articles
My Stockpickr
My Stockpickr Profile
Inbox
Add New Portfolio
Edit My Profile